A Phase 3, Multicenter, Double-Blinded, Randomized, Study to Assess Comparability of a Single Phase 3 Lot and a Single Commercial Lot of 3'-Aminomethylnicotine-P. Aeruginosa r-Exoprotein A Conjugate Vaccine (NicVAX) in Healthy Adult Smokers.

Trial Profile

A Phase 3, Multicenter, Double-Blinded, Randomized, Study to Assess Comparability of a Single Phase 3 Lot and a Single Commercial Lot of 3'-Aminomethylnicotine-P. Aeruginosa r-Exoprotein A Conjugate Vaccine (NicVAX) in Healthy Adult Smokers.

Completed
Phase of Trial: Phase III

Latest Information Update: 11 May 2012

At a glance

  • Drugs Nicotine abuse vaccine (Primary)
  • Indications Drug dependence; Smoking withdrawal
  • Focus Pharmacodynamics; Registrational
  • Sponsors Nabi Biopharmaceuticals
  • Most Recent Events

    • 11 May 2012 Actual end date Oct 2011 added as reported by ClinicalTrials.gov.
    • 11 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 08 Jul 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top